Ontology highlight
ABSTRACT:
SUBMITTER: Matthew Roberts
PROVIDER: MODEL1808150001 | BioModels | 2018-08-15
REPOSITORIES: BioModels
Shibeko Alexey M AM Woodle Samuel A SA Lee Timothy K TK Ovanesov Mikhail V MV
Blood 20120504 4
Recombinant factor VIIa (rFVIIa) is used for treatment of hemophilia patients with inhibitors, as well for off-label treatment of severe bleeding in trauma and surgery. Effective bleeding control requires supraphysiological doses of rFVIIa, posing both high expense and uncertain thrombotic risk. Two major competing theories offer different explanations for the supraphysiological rFVIIa dosing requirement: (1) the need to overcome competition between FVIIa and FVII zymogen for tissue factor (TF) ...[more]